SLAMF6: A Unique Protein Involved in The Immune Response (G114836)

Target Name: SLAMF6

NCBI ID: G114836

SLAMF6

SLAMF6: A Unique Protein Involved in The Immune Response

SLAMF6 (solute carrier family 6) is a protein that is expressed in various tissues and cells in the body. It is a member of the superfamily of transmembrane protein that includes proteins such as the well-known GLUT1, GLUT4, and GLUT5. SLAMF6 is unique in that it is a type of antigen that can induce an immune response in humans, and it is also a potential drug target.

The immune system is a critical component of the body that helps to protect it from infection and disease. When the immune system detects a foreign substance in the body, it mounts an immune response to eliminate the substance. This process is known as inflammation. During the inflammation response, immune cells such as T cells and B cells are activated and begin to divide and differentiate into their respective cell types. One of the key molecules that is involved in this process is the antigen SLAMF6.

SLAMF6 is a transmembrane protein that is characterized by its extracellular domain, which is involved in cell-cell and cell-tissue interactions. It consists of a catalytic active site, a transmembrane domain, and an intracellular tail. The transmembrane domain of SLAMF6 is made up of four conserved domains: an N-terminal alpha-helix, an oligocysteine 鈥嬧?媟esidue, a carboxy-terminal alpha-helix, and a C-terminal T-loop. These domains give SLAMF6 its unique structure and help to determine its functions in the cell.

One of the key functions of SLAMF6 is its ability to induce an immune response in humans. When SLAMF6 is introduced into the body, it is able to interact with the immune cells that are present in the body. This interaction causes the immune cells to become activated and begins to divide and differentiate into their respective cell types. This process is known as inflammation, and it is a critical step in the immune response.

SLAMF6 has also been shown to play a role in the development and progression of various diseases. For example, studies have shown that high levels of SLAMF6 are associated with an increased risk of developing cancer. Additionally, SLAMF6 has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Due to its unique functions and its potential as a drug target, SLAMF6 has drawn significant interest in recent years. Researchers have been studying its structure and function in order to better understand its role in the immune system and its potential as a drug. One of the main challenges in studying SLAMF6 is its complex structure and its ability to interact with the immune system.

In conclusion, SLAMF6 is a unique protein that is involved in the immune response and has the potential to be a drug target. Its functions in the immune system and its potential as a drug target make it an attractive target for further research and study. As research continues, it is likely that SLAMF6 will play an increasingly important role in our understanding of the immune system and its role in the development and progression of various diseases.

Protein Name: SLAM Family Member 6

Functions: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed:11489943, PubMed:16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed:16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed:22184727, PubMed:16920955). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell:B-cell adhesion; the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity)

The "SLAMF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLAMF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets